Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Ragweed Study Data Meet Allergy Therapeutics’ Expectations
RxTrials Institute Drug Pipeline Alert
Oct. 1, 2008 | Vol. 6 No. 40
Ragweed Study Data Meet Allergy Therapeutics’ Expectations
Allergy Therapeutics saw positive results from its Phase III study of Pollinex Quattro Ragweed in treating allergic conditions.
The double-blind, placebo-controlled study enrolled 993 patients in 85 centers in the U.S. and Canada. Subjects were randomized to receive Pollinex Quattro Ragweed or placebo.
Due to a clinical hold placed on the study by the FDA after an adverse event occurred in a previous study, only 381 patients received all four injections. The study met its primary endpoint by demonstrating a 12 percent benefit over placebo in this complete treatment group, the company said.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.